neuroscience research

ADvantage Therapeutics is a clinical-stage biotechnology company developing novel therapeutics to treat neurodegenerative conditions, with a major focus on Alzheimer's Disease. Its lead candidate AD04 is an immuno-stimulant being developed as a disease-modifying therapy for early Alzheimer's Disease. The company was founded in 2021 and has a research team and laboratory at the Vienna BioCenter.

clinical trialsimmunotherapy developmentmRNA therapeutics

Applied Neuro Insights, LLC is a team of UX researchers, designers, and research scientists with decades of experience conducting product usability testing and applied research. They offer remote and in-person UX research and software development services for healthcare, tech, and government clients, and conduct grant-funded neuroscience research for government partners using machine learning and AI to measure cognitive states and predict behavioral outcomes.

Artificial Intelligencecompetitive analysisEEG measurementFocus groupsmachine learningremote testingsoftware developmentsurveysusability testingUX designUX research

Audicin creates scientifically-engineered music combining composed tracks with binaural beats embedded in 360-degree spatial sound, designed by in-house neuroscientists, medical doctors, audio engineers and music composers to guide the brain into states of calm, recovery, or focus. The company also offers the Audicin Sleep Headband, a bluetooth-free, ultra low EMF headband preinstalled with neurosound featuring delta waves for sleep.

audio engineeringmusic compositionspatial sound mixing

Blue Zone Therapeutics is a company developing innovative, effective, and practical treatments targeting age-related diseases in pets, aiming to create 'blue zones' for pets where longevity and vitality are the norm. It brings together scientists and veterinarians to advance pet healthcare through novel approaches and cutting-edge research, integrating science with compassionate care.

gene therapy researchtherapeutic developmentveterinary research

Cogentis Therapeutics is a biotechnology company based in Columbia, Maryland, that discovers and develops first-in-class therapeutics to prevent neurodegeneration and restore brain function. It is committed to finding cures for neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

therapeutic discovery and development

Cortexa Therapeutics is a neuroscience company developing therapies that target biological mechanisms shared across neurodegenerative diseases to restore neuronal homeostasis. Its first program, CRTX-101, targets calcium-permeable AMPA receptors (CP-AMPARs) as mediators of excitotoxic calcium overload in ALS. The company was founded by Nathan Cole following his ALS diagnosis at age 31 and is advised by a scientific board spanning motor neuron biology, ALS neurobiology and excitotoxicity, and translational neurodegeneration research.

drug discoverytherapeutic development

DemeRx is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of addiction. It is developing DMX-1001 (oral noribogaine), an investigational therapy for alcohol use disorder, which affects over 29 million people in the U.S. The company was founded on the research of Dr. Deborah Mash on the neuroplastogen noribogaine, the active metabolite of ibogaine, aiming to restore and reset the brain's addiction circuitry.

clinical developmentdrug development

Eolas Therapeutics is a biotechnology company focused on developing novel therapies for addiction and other neurological disorders. It leverages neuroscience to develop therapies targeting the brain's reward system by modulating specific neural pathways to treat addiction and related disorders.

clinical trialstherapy development

Impairment Science, Inc. is a developer and provider of patent-pending technology for the detection of cognitive impairment. Its flagship product, DRUID, is a mobile app that tests for cognitive and motor impairment from any cause, providing a means for businesses and other organizations to assess the impairment of their employees and members. The company was founded by Dr. Michael Milburn, who conceived the idea in 2016; the app launched in 2018 and the company was renamed Impairment Science, Inc. in 2020.

cognitive and motor impairment testingreal-time monitoring and analysis